Colon News and Research

RSS

USPTO issues three patents to Rosetta Genomics

Rosetta Genomics today announced that the United States Patent and Trademark Office (USPTO) has issued three patents to the company covering the composition of matter of human microRNAs.

4 Feb 2010

ACCP and FIRS honor World Cancer Day

During the 2010: The Year of the Lung campaign, the American College of Chest Physicians (ACCP) and other members of the Forum of International Respiratory Societies (FIRS) are honoring World Cancer Day, February 4, by elevating the awareness of lung cancer in terms of prevalence and prevention, as well as the amount of funding the disease receives for research in diagnosis and management.

4 Feb 2010

Keryx Biopharmaceuticals reaches agreement with FDA on SPA for Phase 3 trial of KRX-0401

Keryx Biopharmaceuticals, Inc. announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a Phase 3 trial for its PI3K/Akt pathway inhibitor, KRX-0401 (perifosine), in patients with refractory metastatic colorectal cancer.

3 Feb 2010

Certain cancer surgeries for low-risk patients may be performed at community hospitals

Low-risk patients who require certain cancer surgeries can have the procedures performed with low operative mortality rates at community hospitals, according to a new study.

3 Feb 2010

Baker's yeast promising against cancer

A researcher at Charles Drew University of Medicine and Science is investigating the potential use of non-pathogenic baker's yeast as a promising, natural therapy for cancer.

3 Feb 2010

Loyola surgeon performs complicated laparoscopic procedure

Mild cases of diverticulitis can be treated with changes in diet, rest and antibiotics. However, Bunch's condition was more serious and the chances of recurrences were high. Her doctors at Loyola University Health System said her best option would be surgery to remove the inflamed section of colon.

2 Feb 2010

$Perifosine holds promise as a single agent for relapsed/refractory Waldenstrom's Macroglobulinemia$

Perifosine holds promise as a single agent for relapsed/refractory Waldenstrom's Macroglobulinemia

Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, today announced that an article entitled "Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia," reporting Phase 2 data demonstrating the single agent activity of perifosine (KRX-0401) for the treatment of advanced Waldenstrom's Macroglobulinemia ("Waldenstrom's"), will appear in the February 1, 2010 issue of the Journal of Clinical Cancer Research.

30 Jan 2010

Johns Hopkins University School of Nursing: Research news

Bridging a Cultural Healthcare Gap—Like other new immigrant groups, Korean Americans' health risks—diabetes, high blood pressure, and cancer—increase after arriving in the U.S. Unfortunately, too many also miss out on needed healthcare services until they are seriously, often chronically ill.

29 Jan 2010

Global market for oncology drugs is forecast to reach $80 billion by 2050

New Medicine's Oncology KnowledgeBASE (nm/OK) residing at http://nmok.net became available on the Internet 10 years ago and, since then, the oncology field has evolved into one of the most challenging, complex and promising drug development sectors, both in terms of its potential contribution to medicine and to its market opportunities.

29 Jan 2010

MedPage Today publishes most read medical stories

Which medical news stories are physicians reading to stay informed about key developments? MedPage Today publishes the Most Read Stories for the Past Week.

28 Jan 2010

IsoRay ships first set of Cesium-131 brachytherapy seeds to Canada

IsoRay, Inc. announced today that it has successfully shipped the first set of Cesium-131 brachytherapy seeds to a Canadian customer for the purpose of furthering research and development of Cesium-131 in Canada. Cesium-131 is currently approved by Health Canada for the treatment of low-risk prostate cancers and has been cleared by the US FDA for treatment of a wide variety of malignant disease (e.g. prostate, head and neck, brain, breast, lung, eye, etc.).

28 Jan 2010

Majority of Americans agree monetary stress can negatively affect health

As we enter a new decade with the hope of rebounding from one of the worst economic downturns in our history, a newly commissioned bank study confirms that nearly 90 percent of Americans agree that monetary stress can negatively affect one’s health. Even more women (91 percent) and older adults (92 percent of those 45 and older) link stress to concerns over money.

28 Jan 2010

GI practices team up with NeuIsys to bring advanced imaging technologies for patients

NeuIsys Imaging System Solutions, LLC, a leader in providing state-of-the-art CT and MR imaging systems to physician practices, announced today that three gastroenterology (GI) practices have entered into agreements with NeuIsys to plan, install, and service the recently FDA approved NeuViz 16 Multi-Slice Computed Tomography (CT) System.

28 Jan 2010

CT colonography remains an effective colorectal cancer screening tool for older individual

Computed tomographic colonography (CTC), also known as virtual colonoscopy, remains effective in screening older patients for colorectal cancer (CRC), produces low referral for colonoscopy rates similar to other screening exams now covered by Medicare, and does not result in unreasonable levels of additional testing resulting from extracolonic findings, according to a study published in the February issue of Radiology.

27 Jan 2010

Neoprobe completes license amendment with The Dow Chemical

Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, announced today that it has completed a license amendment with The Dow Chemical Company for a variety of antibodies used in its proprietary surgical oncology system called radioimmunoguided surgery or RIGS®.

27 Jan 2010

Texas to invest $4.5 mn in cancer research at UT Health Science Center

Texas plans to invest $3 billion in cancer research over the next 10 years and six scientists at The University of Texas Health Science Center at Houston are among the first to receive grants.The researchers, whose grants total $4.5 million, are working to protect girls from cervical cancer, to interrupt tumor growth at the molecular level and to develop a new approach for the treatment of colon cancer, among other cutting-edge projects.

27 Jan 2010